NeoTCR-P1

Background: NeoTCR-P1 is a personalized autologous T cell therapy for treatment of patients with solid tumors... These case studies illustrate for the first time tracking of 3 unique personalized T cell products within a single patient. Shifts in the T cell phenotype of the neoTCR T cell products post-infusion for some, but not all, of the products suggest early signs of T cell engagement with the target.

P1a/1b, N=21, Suspended, PACT Pharma, Inc. | Trial completion date: Dec 2024 --> Aug 2022 | Active, not recruiting --> Suspended | Trial primary completion date: Dec 2022 --> Aug 2022

P1a/1b, N=21, Active, not recruiting, PACT Pharma, Inc. | Recruiting --> Active, not recruiting | N=148 --> 21

P1a/1b, N=148, Recruiting, PACT Pharma, Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2022

This fully personalized NeoTCR-P1 cell therapy is manufactured in fully enclosed, automatable systems for each individual patient with solid tumors. These breakthrough technologies support the on-going Phase 1 clinical trial of personalized engineered autologous NeoTCR-P1 T cell therapies for patients with six different solid tumor types (NCT03970382).

The combination of NeoTCR-P1 dosing plus nivolumab will be tested in a Phase 1b study. This is the first clinical study of an autologous, fully personalized adoptive T cell therapy directed against private tumor-exclusive mutations, generated without using recombinant viral vectors. Research Funding: PACT Pharma

This is the first clinical study of an autologous, fully personalized adoptive T cell therapy directed against private tumor-exclusive mutations, generated without using recombinant viral vectors.